Basilea Pharmaceutica Price To Earning vs. Shares Owned By Insiders
| BSLN Stock | CHF 40.65 0.45 1.09% |
For Basilea Pharmaceutica profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Basilea Pharmaceutica to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Basilea Pharmaceutica AG utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Basilea Pharmaceutica's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Basilea Pharmaceutica AG over time as well as its relative position and ranking within its peers.
Basilea |
Basilea Pharmaceutica Shares Owned By Insiders vs. Price To Earning Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Basilea Pharmaceutica's current stock value. Our valuation model uses many indicators to compare Basilea Pharmaceutica value to that of its competitors to determine the firm's financial worth. Basilea Pharmaceutica AG is number one stock in price to earning category among its peers. It is rated fifth in shares owned by insiders category among its peers making about 0.02 of Shares Owned By Insiders per Price To Earning. The ratio of Price To Earning to Shares Owned By Insiders for Basilea Pharmaceutica AG is roughly 62.58 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Basilea Pharmaceutica's earnings, one of the primary drivers of an investment's value.Basilea Shares Owned By Insiders vs. Price To Earning
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Basilea Pharmaceutica |
| = | 190.88 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Basilea Pharmaceutica |
| = | 3.05 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Basilea Shares Owned By Insiders Comparison
Basilea Pharmaceutica is currently under evaluation in shares owned by insiders category among its peers.
Basilea Pharmaceutica Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Basilea Pharmaceutica, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Basilea Pharmaceutica will eventually generate negative long term returns. The profitability progress is the general direction of Basilea Pharmaceutica's change in net profit over the period of time. It can combine multiple indicators of Basilea Pharmaceutica, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company was founded in 2000 and is headquartered in Basel, Switzerland. BASILEA N operates under Pharmaceuticals And Biosciences classification in Switzerland and is traded on Switzerland Exchange. It employs 160 people.
Basilea Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Basilea Pharmaceutica. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Basilea Pharmaceutica position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Basilea Pharmaceutica's important profitability drivers and their relationship over time.
Use Basilea Pharmaceutica in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Basilea Pharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Basilea Pharmaceutica will appreciate offsetting losses from the drop in the long position's value.Basilea Pharmaceutica Pair Trading
Basilea Pharmaceutica AG Pair Trading Analysis
The ability to find closely correlated positions to Basilea Pharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Basilea Pharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Basilea Pharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Basilea Pharmaceutica AG to buy it.
The correlation of Basilea Pharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Basilea Pharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Basilea Pharmaceutica moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Basilea Pharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Basilea Pharmaceutica position
In addition to having Basilea Pharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Agriculture Thematic Idea Now
Agriculture
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Agriculture theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Agriculture Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Basilea Stock Analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.